Omalizumab

Overview

4.4 out of 5 (8 Reviews)

Credits

1.00

Post Assessment Questions

6

Start Date

1 Jan 2021

Last Review Date

17 Aug 2023

Expiration Date

31 Dec 2023

Estimated Time To Finish

60 Minutes


 
Need Help?  If you have a system or content concerns, please contact support@statpearls.com

Activity Description

Omalizumab received initial approval from the U.S. Food and Drug Administration (FDA) in 2003 for the treatment of moderate-to-severe asthma. Subsequently, in 2014, the drug was also approved for use in patients with chronic idiopathic or spontaneous urticaria in the United States and Europe. Omalizumab is a recombinant humanized immunoglobulin G1 (IgG1) monoclonal anti-IgE antibody utilized to treat allergic asthma and chronic urticaria. This medication works by interacting with the high-affinity receptor Fc-epsilon-RI, typically found on eosinophils, mast cells, and basophils, therefore playing a critical role in preventing the allergic cascade. As a result, omalizumab plays a vital role in managing moderate-to-severe IgE-mediated asthma and, more recently, in treating chronic urticaria. This activity will comprehensively cover the indications, contraindications, mechanisms of action, pharmacokinetics, adverse effects, warnings, precautions, and monitoring requirements of omalizumab. In addition, this activity will also provide updates on some of the critical studies implemented primarily for asthma and include information on urticarial reactions.


Target Audience

This activity has been designed to meet the educational needs of physicians.

Learning Objectives

At the conclusion of this activity, the learner will be better able to:

  • Identify appropriate patients for omalizumab therapy based on indications, such as moderate-to-severe asthma or chronic urticaria.
  • Screen patients thoroughly for eligibility, including total serum IgE levels, potential contraindications, and medical history, before initiating omalizumab treatment.
  • Assess patients' responses to omalizumab treatment by monitoring their symptom improvement, exacerbation frequency, and quality of life measures and adjusting the therapy as needed.
  • Communicate with patients effectively about omalizumab therapy, explaining its benefits, potential risks, and expected outcomes and addressing their concerns or questions.

Disclosures

The Campbell University Jerry M. Wallace School of Osteopathic Medicine (CUSOM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they or their immediate family may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by CUSOM for resolution, to ensure fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

CUSOM will identify, review, and resolve all conflicts of interest that faculty, authors, activity directors, planners, managers, peer reviewers, or relevant staff disclose prior to an educational activity being delivered to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation. Disclosure information for authors, editors, planners, peer reviewers, and/or relevant staff is provided with this activity.

Continuing Education Accreditation Information

 

 

The Campbell University Jerry M. Wallace School of Osteopathic Medicine (CUSOM) is accredited by the American Osteopathic Association to provide osteopathic continuing medical education for physicians. CUSOM designates this enduring material for a maximum of 1.00 AOA Category 1 B Credits and will report CME credits commensurate with the extent of the physician's participation in the activity.

Cancellation Policy: Cancellations must be received in writing and a money back guarantee is provided if not completely satisfied.

  • StatPearls and CUSOM reserve the right to cancel any course due to unforeseen circumstances. StatPearls and CUSOM will not be responsible for other expenses incurred by the participant in the unlikely event that the program is canceled.

Equal Opportunity

  • StatPearls and CUSOM are Equal Opportunity / Affirmative Action / Equal Access Institutions. 

Medium or Media Used:

  • Computer Requirements:  Internet Access
  • E-mail Address

Instructions for Credit

  1. Register for the activity and create a StatPearls login.     
  2. Review the required accreditation information:  Target audience, learning objectives and disclosure information.
  3. Complete the entire self-study activity.
  4. Complete the post-test assessments.
  5. Successfully pass the post-test with a minimum score of 100%.
  6. Complete the evaluation form.
  7. Obtain a certificate.

StatPearls and CUSOM adheres to AOA Standards regarding commercial support of continuing medical education. It is the policy of StatPearls and Campbell that the faculty and planning committee disclose real or apparent conflicts of interest relating to the topics of this educational activity, that relevant conflict(s) of interest are resolved and also that authors and editors will disclose any unlabeled/unapproved use of drug(s) or device(s) during their presentation. Detailed disclosure will be made prior to starting the activity.

The information provided at this CME/CE activity is for continuing education purposes only and is not meant to substitute for the independent medical/clinical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition.

This course is intended for osteopathic physicians who wish to earn AOA CME credit. Take this version of the course to ensure you receive appropriate credit.

 

 
 

Reviews

gerrit h. on 12/28/2021

Rebecca K. on 4/1/2022

Meredith K. on 4/4/2022

Rebecca K. on 1/30/2023

on 8/2/2023

Dr Mekham M. on 9/24/2023

Sharon D. on 11/21/2023

Nithya P. on 3/21/2024

Unlimited Physician CME

Stay up to date on the latest medical knowledge with 6673 CME activities. In these online self-assessment activities, read our reference articles and test your knowledge with more than 7923.5 hours of CME.

Learn About Lifetime CME

Single Activity

Take this single activity

$39 1 activity

6 Month Unlimited Physician CME

Access to all the Unlimited Physician CME activities in all specialties.

$399 per half year per user

1 Year Unlimited Physician CME

Access to all the Unlimited Physician CME activities in all specialties.

$599 per 1 year per user